CN104640546A - 常山酮的剂型以及使用方法 - Google Patents

常山酮的剂型以及使用方法 Download PDF

Info

Publication number
CN104640546A
CN104640546A CN201380027592.XA CN201380027592A CN104640546A CN 104640546 A CN104640546 A CN 104640546A CN 201380027592 A CN201380027592 A CN 201380027592A CN 104640546 A CN104640546 A CN 104640546A
Authority
CN
China
Prior art keywords
dosage form
peroral dosage
pharmaceutically acceptable
acceptable salt
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380027592.XA
Other languages
English (en)
Chinese (zh)
Inventor
E·D·布什
D·麦圭尔
M·B·布劳斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HALO THERAPEUTICS LLC
Original Assignee
HALO THERAPEUTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HALO THERAPEUTICS LLC filed Critical HALO THERAPEUTICS LLC
Publication of CN104640546A publication Critical patent/CN104640546A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380027592.XA 2012-03-29 2013-03-29 常山酮的剂型以及使用方法 Pending CN104640546A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261617356P 2012-03-29 2012-03-29
US61/617,356 2012-03-29
US201361798784P 2013-03-15 2013-03-15
US61/798,784 2013-03-15
PCT/US2013/034616 WO2013149148A2 (en) 2012-03-29 2013-03-29 Dosage forms of halofuginone and methods of use

Publications (1)

Publication Number Publication Date
CN104640546A true CN104640546A (zh) 2015-05-20

Family

ID=49261398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380027592.XA Pending CN104640546A (zh) 2012-03-29 2013-03-29 常山酮的剂型以及使用方法

Country Status (9)

Country Link
US (2) US20150086627A1 (enExample)
EP (1) EP2830628A4 (enExample)
JP (2) JP2015517994A (enExample)
CN (1) CN104640546A (enExample)
AU (2) AU2013237881B2 (enExample)
CA (1) CA2869054A1 (enExample)
HK (1) HK1206646A1 (enExample)
IL (1) IL234841A0 (enExample)
WO (1) WO2013149148A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106539754A (zh) * 2016-11-25 2017-03-29 河北科星药业有限公司 氢溴酸常山酮溶液及其制备方法
CN109793741A (zh) * 2019-03-11 2019-05-24 中国农业科学院兰州兽医研究所 一种常山酮在制备预防口蹄疫病毒感染的药物中的应用
CN113880860A (zh) * 2021-12-08 2022-01-04 北京肿瘤医院(北京大学肿瘤医院) 常山酮衍生物及其药物组合物和用途
CN114469956A (zh) * 2022-01-29 2022-05-13 中国科学技术大学 常山酮在治疗和预防动脉粥样硬化性疾病的药物中的应用
CN116392493A (zh) * 2023-02-02 2023-07-07 四川大学华西医院 一种关于天然活性化合物hf诱导atc细胞凋亡的应用
CN119215052A (zh) * 2024-09-03 2024-12-31 南方医科大学南方医院 常山酮在制备治疗异位骨化的药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335573B2 (en) 2015-12-02 2019-07-02 Cook Medical Technologies Llc Intraperitoneal chemotherapy medical devices, kits, and methods
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
WO2022040566A1 (en) * 2020-08-21 2022-02-24 The Regents Of The University Of California Methods and uses of halofuginone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
US20110263532A1 (en) * 2008-08-11 2011-10-27 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512410B2 (enExample) * 1974-02-27 1980-04-02
JPS5732230A (en) * 1980-07-18 1982-02-20 Parke Davis & Co Instetine-soluble capsule
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
JPH04346930A (ja) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
US5356634A (en) * 1992-11-13 1994-10-18 Eastman Chemical Company Controlled-release delivery system
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
CN100591336C (zh) * 2002-11-08 2010-02-24 汪建平 菱角提取物及其使用方法
US7705049B2 (en) * 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
US20050208134A1 (en) * 2004-02-25 2005-09-22 Shlomo Magdassi Biocompatible polymeric beads and use thereof
US20070281961A1 (en) * 2006-06-05 2007-12-06 Brite Age Modified Compositions And Methods For Enhancing Brain Function
EP2114409B1 (en) * 2007-01-21 2013-11-20 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
TWI478710B (zh) * 2007-11-30 2015-04-01 Univ California 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
US20110263532A1 (en) * 2008-08-11 2011-10-27 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106539754A (zh) * 2016-11-25 2017-03-29 河北科星药业有限公司 氢溴酸常山酮溶液及其制备方法
CN109793741A (zh) * 2019-03-11 2019-05-24 中国农业科学院兰州兽医研究所 一种常山酮在制备预防口蹄疫病毒感染的药物中的应用
CN113880860A (zh) * 2021-12-08 2022-01-04 北京肿瘤医院(北京大学肿瘤医院) 常山酮衍生物及其药物组合物和用途
CN114469956A (zh) * 2022-01-29 2022-05-13 中国科学技术大学 常山酮在治疗和预防动脉粥样硬化性疾病的药物中的应用
CN116392493A (zh) * 2023-02-02 2023-07-07 四川大学华西医院 一种关于天然活性化合物hf诱导atc细胞凋亡的应用
CN119215052A (zh) * 2024-09-03 2024-12-31 南方医科大学南方医院 常山酮在制备治疗异位骨化的药物中的应用
CN119215052B (zh) * 2024-09-03 2025-09-02 南方医科大学南方医院 常山酮在制备治疗异位骨化的药物中的应用

Also Published As

Publication number Publication date
AU2018200167A1 (en) 2018-02-01
WO2013149148A2 (en) 2013-10-03
JP2018203790A (ja) 2018-12-27
EP2830628A2 (en) 2015-02-04
HK1206646A1 (en) 2016-01-15
JP2015517994A (ja) 2015-06-25
WO2013149148A8 (en) 2013-11-14
AU2013237881B2 (en) 2017-10-12
EP2830628A4 (en) 2016-05-25
IL234841A0 (en) 2014-12-31
WO2013149148A3 (en) 2015-04-16
US20150086627A1 (en) 2015-03-26
CA2869054A1 (en) 2013-10-03
AU2013237881A1 (en) 2014-10-16
US20180193276A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
CN104640546A (zh) 常山酮的剂型以及使用方法
US20200085807A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US9925174B2 (en) Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
JP6359022B2 (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
US20230090391A1 (en) Omecamtiv mecarbil tablet
AU2016213722A1 (en) Solid dispersion of rifaximin
WO1999029327A1 (en) Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance
CN102036656A (zh) 含有蜡的缓释制剂
JP2008069159A5 (enExample)
KR20170092719A (ko) 안티센스 조성물 및 그의 제조 및 사용 방법
JP2019001787A (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
TW200304379A (en) Pharmaceutical composition
EP3684344B1 (en) Delayed release deferiprone tablets and methods of using the same
WO2016073510A1 (en) Methods of administering amantadine compositions
JP7652787B2 (ja) ベンズイミダゾール誘導体化合物を含有する医薬組成物
JP4812225B2 (ja) 生理活性ペプチド含有腸溶性製剤
US20210369624A1 (en) Solid oral dosage form having excellent dissolution properties
JPWO2002004016A1 (ja) 生理活性ペプチド含有腸溶性製剤
JP2010529125A (ja) 胃食道逆流疾患の治療に有用な組成物
WO2020104955A1 (en) Pharmaceutical compositions of acotiamide and proton pump inhibitor
EP3981470A1 (en) Enteric-coated preparation comprising xanthine oxidase inhibitor
KR20230112343A (ko) 두타스테리드 및 타다라필을 포함하는 복합제제 및 이의 제조방법
WO2011052499A1 (ja) 貯蔵安定性が改善された医薬組成物
WO2011052500A1 (ja) ワックス安定製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150520

WD01 Invention patent application deemed withdrawn after publication